Proteintech Interview with Dr John Maher
Proteintech Interview with Dr John Maher
In this video, Proteintech's Chief Scientific Officer, Dr Deepar Shankar interviews Dr John Maher, CAR_T Specialist of King's College London prior to Proteintech's first Cancer Immunotherapy Meeting for Early Career Researchers.
Dr. John MaherClinical Immunologist, Kings College London, UK |
 |
|
"CAR T-Cell Immunotherapy of Solid Tumors: Learning from the Clinic and Lab in Parallel" |
|
|
Dr John Maher is a clinical immunologist who leads the "CAR Mechanics" research group within King's College London. He played a key role in the early development of second generation (CD28) CAR technology while a visiting fellow at Memorial Sloan Kettering Cancer Center, an approach that has achieved clinical impact in haematological malignancies. His research group is focused on the development of adoptive immunotherapy using CAR engineered and gamma delta T-cells, with a primary emphasis on solid tumour types. He is also the scientific founder and chief scientific officer of a spin-out company named Leucid Bio. In addition, he is a consultant immunologist within King's Health Partners and Eastbourne Hospital. |
